Neurocrine Biosciences Inc (NBIX)
NasdaqGS · Price as of · Nasdaq Real Time Price
- Analysts27
- Implied upside+37.3%
- Target range$165.00 to $249.00
- EPS expected$2.72 +25%
- A year ago$2.17
- Revenue expected$1.04B +31%
- Estimate range$2.07 to $3.39
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | August 5, 2026 | FORM 4 |
| S-8 | July 31, 2026 | S-8 |
| 8-K/A | July 31, 2026 | 8-K/A |
| 10-Q | July 31, 2026 | 10-Q |
| 4 | July 30, 2026 | FORM 4 |
| 8-K | July 30, 2026 | 8-K |
| SCHEDULE 13G/A | July 27, 2026 | View on EDGAR |
| 4 | July 13, 2026 | FORM 4 |
Frequently asked questions
When does NBIX report earnings?
Neurocrine Biosciences Inc (NBIX) is scheduled to report quarterly results on October 28, 2026, after the close. The 16-analyst consensus is $2.72 per share on revenue of $1.04B for the quarter ending September 30, 2026, against $2.17 and $794.9M a year earlier. It has beaten the consensus EPS estimate in 3 of the last four quarters.
What do analysts expect for NBIX?
27 analysts cover Neurocrine Biosciences Inc (NBIX). The consensus rating is Strong buy. The average price target is $211.57, in a range of $165.00 to $249.00.
Are insiders buying or selling NBIX?
We have no qualifying Form 4 insider purchases or sales on record for Neurocrine Biosciences Inc (NBIX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see NBIX SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed August 5, 2026.